HOME >> BIOLOGY >> NEWS
Beware cancer, insomnia and liver disease UH students are taking aim

HOUSTON, June 1, 2004 Targeting a range of diseases and disorders, three University of Houston students won awards at a recent symposium for research in liver disease, cancer and insomnia.

The Intercultural Cancer Council (ICC) recently hosted its 9th Biennial Symposium on Minorities, the Medically Undeserved and Cancer in Washington, D.C. The ICC promotes policies, programs, partnerships and research to eliminate the unequal burden of cancer among racial and ethnic minorities and medically undeserved populations in the U.S. and its associated territories.

Among the 1,500 who attended this ICC symposium, UH students accounted for 18 of the 300 students from across the nation who participated. Three UH students from the College of Natural Sciences and Mathematics (NSM) swept the undergraduate research competition, taking home half of the six awards handed out in that category. Each received a medal to recognize their achievements and a cash award of $500.

"We are extremely proud of all our students who represented the University of Houston," said John Bear, dean of UH's College of Natural Sciences and Mathematics. "And we're particularly pleased with the acknowledgement received by our three outstanding students who presented award-winning work, as well as commend the faculty members for engaging undergraduates in the research process."

Jose Figueroa, a senior biology major in NSM's Biology and Biochemistry department at UH, won his poster award for research in biological clocks. Also known as circadian rhythms, biological clocks are the mechanisms that control sleep/wake cycles in living organisms. Working in the Neurobiology Laboratory with Michael Rea, UH professor of biology and biochemistry, Figueroa assists with the lab's focus on understanding the biological clock so that it may eventually lead to therapeutic agents that can treat sleeping/waking disorders, such as advanced sleep phase syndrome, jet lag and insomn
'"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
1-Jun-2004


Page: 1 2 3

Related biology news :

1. Beware of leap year when predicting climate change, warns researcher
2. Beware the frozen vegetable ice pack to ease pain
3. Beware The Pumpkin Preyer
4. IBD (Crohns, Colitis) joins cancer, inflammatory diseases in associated blood vessel growth
5. Purdue scientists: To stop cancer, keep your Icmt away from your Ras
6. Drug developed for rare disease may help millions more as treatment for cancer, autoimmune diseases
7. Telltale prostate cancer protein key to breast cancer, too
8. UGA receives $6.7 M grant that will add knowledge in fights against cancer, Parkinsons disease
9. Isolation of ferret protein promising for cancer, reproductive studies
10. UNC studies target molecular defects implicated in cancer, genetic diseases
11. Common human virus may be associated with colon cancer, according to Temple researchers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Beware cancer insomnia and liver disease students are taking aim

(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
Cached News: